Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria

  • Haematologica. 2022 Jun 1;107(6):1483-1488. doi: 10.3324/haematol.2020.265868.
Jun-Ichi Nishimura  1 ,  Kiyoshi Ando  2 ,  Masayoshi Masuko  3 ,  Hideyoshi Noji  4 ,  Yoshikazu Ito  5 ,  Jiri Mayer  6 ,  Laimonas Griskevicius  7 ,  Christoph Bucher  8 ,  Florian Müllershausen  8 ,  Peter Gergely  8 ,  Izabela Rozenberg  8 ,  Anna Schubart  8 ,  Raghav Chawla  8 ,  Jean-Michel Rondeau  8 ,  Michael Roguska  8 ,  Igor Splawski  8 ,  Mark T Keating  8 ,  Leslie Johnson  8 ,  Rambabu Danekula  8 ,  Morten Bagger  8 ,  Yoko Watanabe  8 ,  Börje Haraldsson  8 ,  Yuzuru Kanakura  9
Affiliations
  • 1. Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita. [email protected].
  • 2. Department of Hematology and Oncology, Tokai University, Isehara.
  • 3. Department of Hematology, Endocrinology and Metabolism, Niigata University Medical and Dental Hospital, Niigata.
  • 4. Department of Cardiology and Hematology, Fukushima Medical University, Fukushima.
  • 5. Department of Hematology, Tokyo Medical University, Shinjuku-ku, Tokyo.
  • 6. Department of Internal Medicine, Hematology and Oncology, Masaryk University Hospital and Faculty of Medicine, Brno, Czech Republic.
  • 7. Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos and Institute of Clinical Medicine, Vilnius University, Vilnius.
  • 8. Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo.
  • 9. Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan; Sumitomo Hospital, Osaka.
PMID: 35263983 DOI: 10.3324/haematol.2020.265868
Products